This content is viewable by members only. Visit MY ACCOUNT on the top menu to log in or to register for a 30 day free trial or purchase a subscription for UV Reporter 1 Year Single Membership or UV Reporter 1 Year Group Membership - $189 for first member and $25 for each additional member.
Aytu BioScience Completes Clinical Trial of Healight™ UV-A Light Catheter Technology
ENGLEWOOD, CO / ACCESSWIRE / February 11, 2021 / Aytu BioScience, Inc. (NASDAQ: AYTU), reported financial results for its fiscal second quarter ending December 31, 2020, last week, and disclosed completion of the first clinical study evaluating the company’s Healight™ ultraviolet A light catheter technology. “This is an important milestone, and we look forward to continuing discussions with the FDA on the advancement of the Healight technology and reporting the results of the clinical study upon the upcoming publication,” Josh Disbrow, Chief Executive Officer of Aytu BioScience, commented. See https://www.sec.gov/Archives/edgar/data/1385818/000143774921002591/ex_223748.htm
Published in Product
More from ProductMore posts in Product »
- PureAir Room 500 X from Vent-Axia Has Seven Stage Purification Process Including UV Sterililzation
- Toyoda Gosei Develops Compact UV-C LED Water Purification Device Applicable in Tight Spaces
- Dyson Humidifier with Ultraviolet Disinfection Makes 2023 Best of List
- Solar Windows from Ubiquitous Energy Convert Ultraviolet and Infrared Waves into Energy
- Orbitrap a Scaled-Down Drug Discovery Device Using Pulsing Ultraviolet Laser to Scan for Alien Life